help button home button Am J Pathol ASIP WHAT IS IT?
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Order Full text via Infotrieve
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kajita, T.
Right arrow Articles by Hugli, T. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kajita, T.
Right arrow Articles by Hugli, T. E.

American Journal of Pathology, Vol 138, 1359-1369, Copyright © 1991 by American Society for Investigative Pathology


REGULAR ARTICLES

Evidence for in vivo degradation of C3a anaphylatoxin by mast cell chymase. I. Nonspecific activation of rat peritoneal mast cells by C3ades Arg

T Kajita and TE Hugli
First Department of Pediatrics, Dokkyo School of Medicine, Tochigen- ken, Japan.

The anaphylatoxin C3a (125I-HC3a) is extensively degraded when exposed to isolated rat mast cells (RMC). Degradation occurs without prior stimulation of these cells. The protease responsible for C3a degradation has been identified as chymase. Mixed peritoneal cells, containing equal numbers of mast cells compared with incubates containing more highly purified RMC, promoted less degradation of the C3a molecule than did the purified RMC. These variable levels of spontaneous activation (ie, chymase release) of RMC in vitro were concluded to be a function of the cellular handling and isolation procedures. No degradation occurred when low levels of 125I-HC3ades Arg (10(-8) mol/l [molar]) were introduced in the peritoneum of a rat, unless the mast cells were stimulated by prior introduction of specific activators. Evidence that the enzyme being released in the peritoneal cavity of rats was chymase was provided both by its appearance after adding specific mast cell activators (ie, compound 48/80 and anti-IgE [gamma E immunoglobulin]) and by inhibition with chymostatin. Because 125I-HC3ades Arg at low levels (10(-8) mol/l) was not degraded in the rat peritoneum, expression of chymase by the rat mast cells could be monitored in situ during mast cell stimulation. 125I-HC3ades Arg was rapidly converted (in 2 to 5 minutes) to smaller fragments in the peritoneal cavity of the rat after either 10 micrograms of compound 48/80 or anti-IgE was injected. Introduction of higher levels of HC3a or HC3ades Arg (2.5 to 5.0 x 10(-6) mol/l) to the peritoneal cavity of the rat stimulated both chymase release and HC3a degradation without other mast cell activators being present. HC3ades Arg was equally as effective in vivo as HC3a in stimulating the rat peritoneal mast cell to release chymase. It was concluded that the mechanism of RMC activation by C3a (C3ades Arg) was nonspecific and similar to the process by which polyamines and polycations stimulate mast cells, as C3a is a highly cationic molecule. The fact that C3a may in turn be destroyed in minutes by the recruited protease (chymase) defines a potentially important physiologic control mechanism. This cellular control process, demonstrated here for rat mast cells, may function in other animals, including man, for regulating tissue levels of factors such as the anaphylatoxins that are potentially capable of mast cell activation through nonspecific (polycationic) mechanisms.





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1991 by the American Society for Investigative Pathology.